{"id":"anagrelide-retard","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Tachycardia"}]},"_chembl":{"chemblId":"CHEMBL1200759","moleculeType":"Small molecule","molecularWeight":"292.55"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Anagrelide works primarily through inhibition of phosphodiesterase 3 (PDE3), which leads to decreased platelet aggregation and reduced megakaryocyte proliferation. The retard formulation provides extended-release delivery to maintain therapeutic levels while potentially improving tolerability. It is used to reduce elevated platelet counts in patients with thrombocythemia.","oneSentence":"Anagrelide is a phosphodiesterase 3 inhibitor that reduces platelet production by inhibiting megakaryocyte maturation and proliferation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:01:33.131Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Essential thrombocythemia (ET) — reduction of elevated platelet counts"},{"name":"Polycythemia vera with thrombocytosis"}]},"trialDetails":[{"nctId":"NCT01230775","phase":"PHASE3","title":"Anagrelide Retard vs. Placebo: Efficacy and Safety in \"At-risk\" Patients With Essential Thrombocythaemia","status":"COMPLETED","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2010-12","conditions":"Essential Thrombocythaemia","enrollment":146},{"nctId":"NCT02076815","phase":"PHASE3","title":"Anagrelide Retard in Essential Thrombocythemia","status":"COMPLETED","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2014-02","conditions":"Essential Thrombocythemia","enrollment":106}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Anagrelide retard 2 mg film coated tablet","ANAT2"],"phase":"phase_3","status":"active","brandName":"Anagrelide retard","genericName":"Anagrelide retard","companyName":"AOP Orphan Pharmaceuticals AG","companyId":"aop-orphan-pharmaceuticals-ag","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anagrelide retard is a small molecule inhibitor of the phosphodiesterase 3 enzyme, used to treat Essential Thrombocythemia. It is a Phase III medication that has been studied in clinical trials, including a randomized, multicenter, double-blind, active controlled study to compare its efficacy to Thromboreductin.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}